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Objectives: To analyze risk factors for chylothorax in infants after congenital heart surgery and the efficacy of
median chain triglyceride diet (MCT). To develop our therapeutic pathway for the management of chylothorax.
Patients and methods: Retrospective review of the institutional surgical database and patient charts including
detailed perioperative informations between 1/2000 and 10/2006. Data analyzing with an elimination regression
analysis.
Results: Twenty six out of 282 patients had chylothorax (=9.2%). Secondary chest closure, low body weight, small
size, longer cardiopulmonary bypass (242 ± 30 versus 129 ± 5 min) and x-clamp times (111 ± 15 versus 62 ± 3
min) were significantly associated with chylothorax (p < 0.05). One patient was cured with total parenteral nutrition
(TPN) and one without any treatment. 24 patients received MCT-diet alone, which was successful in 17 patients
within 10 days. After conversion to regular alimentation within one week only one chylothorax relapsed. Out of 7
patients primarily not responsive to MCT-diet, 2 were successfully treated by lysis of a caval vein thrombosis, 2 by
TPN + pleurodesis + supradiaphragmatic thoracic duct ligation, one by octreotide treatment, and two patients
finally died.
Conclusions: Chylothorax may appear due to injury of the thoracic duct, due to venous or lymphatic congestion,
central vein thrombosis, or diffuse injury of mediastinal lymphatic tissue in association with secondary chest
closure. Application of MCT alone was effective in 71%, and more invasive treatments like TPN should not be used
in primary routine. After resolution of chylothorax, MCT-diet can be converted to regular milk formula within one
week and with very low risk of relapse.
Introduction
Chylothorax is a frequent and serious complication
associated with congenital heart surgery, which occurs
with an incidence between 0.5% to 6.5%. It may be
caused either by injury of the thoracic duct, increased
pressure in the systemic veins exceeding that in the
thoracic duct, or a central vein thrombosis [1-4]. The
diagnosis is based on the milky or opalescent appear-
ance of the fluid from the pleural spaces with high levels
of triglycerides (>110 mg/dl), proteins (>20 g/L), and
lymphocytes (>80% of cells) [3]. These large losses of
nutrients and immune cells put patients at risk of mal-
nutrition, impair their immune system and may also
lead to respiratory problems with the need of a pleural
drain [5]. Published treatment strategies which aim to
decrease or stop the lymphatic lymph flow are: long
chain fatty acid free, median chain triglyceride (MCT)-
enriched diet [2,6,7], total parenteral nutrition (TPN)
[6,7], octreotide therapy [2,3,5,7]), optimization of
hemodynamics (recanalisation of closed central veins),
or closing the leakages by supraphrenic ligation or
pleurodesis[8-10]. We reviewed our institutional data-
base on congenital heart disease in a high risk popula-
tion of newborns and infants for possible reasons of
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peutic approach.
Patients and methods
We carried out a systematic retrospective review of our
institutional database on all surgeries of congenital heart
disease in children within their first year of life at the
Freiburg University Hospital between January 2000 and
October 2006. Chylothorax was defined as the presence
of significant pleural drainage losses with typical clinical
appearance after the 5th day post op. Regularly we
started milk feeding via the stomach tube as early as
possible, regularly at day 3 postoperative. Therefore the
typical white appearance of chylothorax was clearly
observable at day 5 postoperative.
Risk factors for chylothorax
Table 1 lists the potential risk factors which have been
analyzed in our database. Additionally we assessed the
duration of drainage, the day of maximum loss of chy-
lous and the type and duration of treatment (fatty acid-
free MCT-enriched diet, TPN, octreotide, recanalisation
of thrombosed veins by lysis, supraphrenic ligation, sur-
gical pleurodesis) as well as the procedure after success-
ful treatment of chylothorax.
Statistics
Group comparison was performed with the Mann-Whit-
ney-Test (SPSS program Version 15). A p-value <0.05
was considered to be statistically significant. The para-
meters (listed in Table 1) were put in a multivariate bin-
ary logistic regression analysis with backward
elimination (PROC logistic, SAS Version 9). In children
who received repeated surgery in the first year of life
only the data of the last operation was used for
investigation.
Treatment of chylothorax
On institutional consent, most patients with chylothorax
were treated primarily with long chain fatty acid-free
diet enriched with 1-2% MCT for at least 10 days. Addi-
tional treatment strategies were applied following clini-
cal decision.
Results
We analyzed the data of 282 neonatal or infant opera-
tions on congenital heart disease (between January 2000
and October 2006) 26 out of 282 patients (=9.2%) were
diagnosed with chylothorax. The median duration of the
chylous pleural effusions was 9 days (ranging from 3 to
59 days). The daily volume of chyle was 43 (18-
183 ml/kg, [median, min-max], Table 2). In most cases,
chylothorax was diagnosed after the correction of the
transposition of great arteries (TGA), atrioventricular
septal defect (AVSD) and after Norwood-I procedure in
hypolastic left heart syndrome (HLHS, Table 3). The
results of the multivariate regression analysis show that
secondary chest closure (p < 0.0012 [1.8; 11.7]), long
CPB-time (p = 0.0077 [2.2; 157.1]), postoperative seda-
tion (p = 0.0017 [1.8; 11.7]) and reintubation (p = 0.001
[2.9; 24.9]) are associated with chylothorax. Duration of
cardiopulmonary bypass (242 ± 30 min versus 129 ± 5
min) and the x-clamp-time (111 ± 15 min versus 62 ±
2.7 min) were longer in patients who subsequently
developed chylothorax, p < 0.05 (Table 1). Patients with
chylothorax had comparatively lower weight (median 3.9
± 0.28 kg versus 4.8 ± 0.01 kg) and were of smaller
body size (median 55.1 ± 1.4 cm versus 58.3 ± 0.5 cm),
p < 0.05 (Table 4).
In 24 out of 26 patients with chylothorax, treatment
was started with MCT diet. One patient was put on
TPN (recovered from chylothorax), another recovered
from chylothorax without any treatment. MCT-diet was
successful in 17 out of 24 cases (=71%) and pleural drai-
nages could be removed after a median of 9 days. After
removal of the pleural drainages, gradual change of the
diet to normal fatty nutrition was carried out success-
fully in 16 out of 17 patients (=94%) within one week
(breast feeding in 10 cases). There was only one relapse
of chylous effusion which required pleural drainage for
one week (Figure 1).
MCT-diet alone was not successful in 7 out of
24 (=29%) patients. These 7 patients had much more
daily drainage losses compared to patients successfully
treated with MCT-diet (median loss 119 ml/kg/day ver-
sus 40 ml/kg/day). In 4 out of these 7 patients (=57%), a
subclavian, innonimate or a superior caval vein
Table 1 Variables used for regression analysis
Anamnestical
parameters
age, gender, weight, height
Parameters during
operation
CPB duration If yes, perfusions-time, x-clamp-time, rectal
temperature
postoperatively The duration of sedation*, relaxation*, peritoneal dialysis, secondary
chest closure
Other parameters Pre-operated, re-operation, death
* The number of days of continuous iv-application were analyzed, for results see also table 2
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these 4 patients was successful in reopening the vein,
but resolved chylothorax only in 2. In one patient who
had a contraindication for a lysis therapy, chylothorax
was successfully treated with TPN and supradiaphrag-
matic ligation of the thoracic duct. The 2 patients with
remaining chylothorax suffered from severe capillary
leakage and in one of these, the thrombosis appeared.
The thrombosis was secondary to chylothorax, as it had
been ruled out at the beginning of treatment. This sug-
gests that the thrombosis resulted from the massive
pleural drain losses and coagulation factor imbalances.
Further attempts to treat chylous pleural and abdominal
effusions including TPN, octreotide treatment, supraph-
renic duct ligation and pleurodesis proved unsuccessful
in both these patients. Both patients suffered from
severe hemodynamic problems (elevated central venous
pressures, low cardiac output) and died from intensive
medicine complications on day 55 and 59 respectively
(= 8% of all newborns/infants with chylothorax, = 29%
of the patients unresponsive to MCT-diet).
Table 2 Characteristics of patients with chylothorax
median (range)
Duration of drainage (days) 9 (3- 59)
Duration of sedation (days) 2 (0-20)
Duration of relaxation (days) 0 (0-4)
Max. loss of chyle within 24 hours (ml/kg) 43 (18 - 183)
Day of max. loss (post-op day) 8 (5-52*)
Start of MCT-diet (post op-day), n = 24 9 (5-52*)
Start of octreotide (post op-day); n = 3 10, 17, 20
Duration of TPN treatment (days); n = 4 6 (2 -54)
Lowest serum total protein (g/l)**, *** 39 (30-49)
Lowest serum antithrombin III (%)** 59 (32-85)
Lowest serum quick (%)** 75 (42-101)
Lowest serum immunoglobulin G (mg/dl)** 220 (64-346)
* One patient developed chylothorax the first time on post-op-day 51st
**Lab-analyses during chylous-loss
*** Significantly lower compared to day 5 post-op analyses [40 (33-50) g/l],
p < 0.05
Table 3 Diagnosis of the patients with chylothorax
Diagnosis Frequency in patients with Chylothorax Frequency in patients without Chylothorax
HRHS 3 (8%)* 36***
HLHS 4 (11%)** 36****
AVSD 4 (16%)***** 25
VSD 1 (3%) 41
ASD 1 0
TAC 2 (33%) 6
TGA 7 (28%) 25
DORV 1 (13%) 8
TOF 1 (4%) 29
CoA 1 (5%) 20
ALVS 1 2
others 28
* chylothorax in HRHS in one patient occurred after a neonatal operation (reconstruction of the RVOT), in one patient after bidirectional Glenn procedureand in
one patient after valvuloplasty at the age of five month. CVP after bidirectional Glenn operation was below 18 mm of mercury during ventilation.
** In HLHS two cases of chylothorax occurred during the Norwood I procedure, two cases of chylothorax occurred after the bidirectional Glenn anastomosis. CVP
was regular (14 - 16 mmHg) after extubation in both patients.
*** 9 out of 36 patients were bidirectional Glenn operations
**** 12 out of 36 operations were bidirectional Glenn operations
***** 2 out of 4 patients with chylothorax after correction of AVSD were suffering on Down-syndrome; 6 out of 25 children without chylothorax after correction
of AVSD were without Down syndrome.
Most patients developed chylothorax after the correction of a transposition the great vessels. After HLHS and AVSD operations the chylothorax was seen as well.
Abbr.: HRHS = hypoplastic right heart syndrome, HLHS = hypoplastic left heart syndrome, AVSD = atrium ventricular septal defect, VSD = ventricular septal
defect, ASD = atrium septal defect, TAC = truncus arterious communis, TGA = transposition of the great vessels, DORV = double outlet right ventricle, TOF =
Tetralogy of Fallot, CoA = coarctation of the aorta; ALVS = aorto left ventricular shunt
Table 4 Patient characteristics and operation variables
no chylothorax chylothorax p
Number of patients (%) 256 (92.5%) 26 (7.5%)
Age (days) 111 ± 5.8 82.4 ± 18.9 n. s.
Weight (kg) 4.8 ± 0.01 3.9 ± 0.28 <0.05
Height (cm) 58.3 ± 0.5 55.1 ± 1.4 <0.05
male: female 56 (%): 44 (%) 50 (%): 50 (%) n. s.
Operations on CPB 83 (%) 85 (%) n. s.
CPB duration (min) 129 ± 4.7 242.6 ± 29.6 <0.05
x-clamp time (min) 61.6 ± 2.7 110.6 ± 15.3 <0.05
Temperature (°C) 30.6 ± 0.31 28.7 ± 1.04 n. s.
Chylothorax patient are smaller and lighter and have a longer CPB duration
and x-clamp time than non-chylothorax patients. Abbr.: n.s = not significant
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Figure 1 Management of 26 patients with chylothoraces. Chylothoraces were first-line treated with MCT-diet, which was effective in 71%. All
patients but one tolerated rapid conversion to regular nutrition formula within 1 week after the chylothorax had disappeared. In 4 patients
different additional treatments were effective. Two patients (grey setting box), both with low cardiac output and persistent capillary leackage
died with remaining chylothorax despite numerous treatment attempts.
Biewer et al. Journal of Cardiothoracic Surgery 2010, 5:127
http://www.cardiothoracicsurgery.org/content/5/1/127
Page 4 of 7Chylothorax persistent 
longer than 5 days after 
surgery 
Central veins open 
Good circulatory 
function 
Start fatty acid-free MCT-enriched diet  
(minimum 10 days)
Check venous drainage 
Obstruction/closure of 
central veins 
Consider causal therapy: 
lysis, interventional, 
thrombectomy, … 
Check hemodynamics:  
low cardiac output?  









high losses of chyle? 
Switch to regular feeding 
formular within 1 week 
Consider oral low fat formula with 
intravenous lipids, TPN, 




Figure 2 Recommendation for the management of chylothorax. Possibly treatable causes for chylothorax should be ruled out or treated
before symptomatic therapy is started. Before more invasive and long-lasting therapies are started, one attempt to treat chylothorax with MCT-
diet should be done (efficacy to treat chylothorax is 70% within acceptable treatment period). Abbr.: MCT = fatty acid-free MCT-enriched diet;
TPN = total parenteral nutrition.
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Compared to the data found in the quoted literature
[1-3], our study shows a high, 9% incidence of chy-
lothorax in the high-risk newborn and infant population.
Based on our study different reasons for chylothorax
may exist, i.e. surgical damage of the thoracic duct, but
also damage of minor chylous vessels, as well as lym-
phatic congestion due to elevated central venous pres-
sure or central vein thrombosis[2,4,6]. Our observation
that chylothorax is associated with secondary chest clo-
sure supports the thesis that non-specific mediastinal
(lymphatic) tissue damage and postoperative impaired
hemodynamics should be considered as important fac-
tors in the pathophysiology of chylothorax. Chylothorax
was present in 28% of the arterial switch operations (7
out of 25 patients). In contrast, chylothorax occurred
only in three patients with univentricular heart after
bidirectional Glenn procedure, all without evidence for
highly elevated CVP. This data suggest that elevated
CVP is not the major driver for chylothorax in our
series.
Our study shows that 10-day treatment of chylothorax
using a long chain fatty acid free MCT-enriched diet
was effective in 71% of affected patients. Moreover, 90%
of recovered patients tolerated well the rapid conversion
[1] to regular alimentation (mostly breast feeding)
within one week after recovery, without relapse of chy-
lothorax (Figure 1). This is especially important for new-
borns and infants as the growing brain is strongly
dependent on the supply of balanced fatty acid nutrition
[11] and breast feeding encourages mother-child interac-
tion and neurological development [12]. Therefore we
would not recommend a prophylactic administration of
MCT diet after complex heart surgery without evidence
of chylothorax. In contrast, TPN has much more side
effects and has no higher efficacy in treating chylothorax
[12]. Panthongviriyakul and Bines suggest using TPN in
cases with elevated central venous pressures >15 mmHg
[1]. When deciding over the use of TPN, its possible
side-effects should be considered, such as an increased
risk of nosocomial infections [13,14]. Patients with TPN
are hungry and distressed, requiring sedatives that may
have a detrimental effect on blood pressure and hemo-
dynamics, and prolong the weaning of the respirator.
Patients on TPN are dependent on central venous lines,
through which they receive high osmolar fluids that
ensure an adequate supply of calories. This puts them at
risk of developing central vein thrombosis [15]. To
avoid central lines, an oral nutrition with a low fat for-
mula (basic-f) and intravenous application of lipids may
be practical. Since central vein thrombosis has been
identified as a possible cause of chylothorax, lysis treat-
ment or an interventional procedure should be
considered if a central vein thrombosis is diagnosed
[16,17]. The limitations of our study are the restricted
number of patients, heterogeneous diagnoses and opera-
tions, and the retrospective design. Due to these limita-
tions, we could not methodically analyze the impact of
the loss of pro- and anti-coagulation factors, total pro-
tein and immunoglobulins on infections, thromboses
and on the outcome (Table 2).
In our study, patients who did not respond to MCT-
diet suffered higher chylous pleural losses and carried a
limited prognosis of viability, as the reasons for chyle
separation were not resolved. We therefore recommend
an enlarged diagnostic work-up in cases where the
patient’s condition does not improve after ten days of
MCT-diet (ruling out secondary central vein thrombosis,
optimizing hemodynamics). Especially venous obstruc-
tion might be treated by transcatheter interventions
(balloon angioplasty, mechanical thrombolysis or stent-
ing) [18] or even by surgical thromectomie [16]. It is
also important to consider early application of additional
and more invasive treatment strategies like TPN, octreo-
tide, supraphrenical ligation or pleurodesis in such cases
(Figure 2).
In conclusion, we found that newborns and infants
who have undergone complex cardiac surgery are at the
highest risk for chylothorax. These patients’ risk is
further increased in cases with secondary chest closure.
In the majority of the patients (71% in our study), chy-
lous leakage was temporary and could be treated effec-
tively using a long chain fatty acid-free MCT-enriched
diet, suggesting that the general use of longer and more
invasive treatment is not necessary. MCT-enriched diet
has no considerable negative impact on the general state
of health, which is of special importance for newborns
and infants and their particular nutritional requirements.
Patients with persistent chylothorax carry a limited
prognosis, which means that application of additional
treatment strategies including surgical options should be
considered in time. In particular, central vein thrombo-
sis should be treated energetically.
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